Welcome to our dedicated page for Precigen SEC filings (Ticker: PGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UltraCAR-T, AdenoVerse, cash runway, and clinical milestones—Precigen’s SEC documents pack dense science and finance into hundreds of pages. Finding the R&D spend that fuels its gene-therapy platforms or tracing when executives sell shares can feel overwhelming. Stock Titan’s AI turns that complexity into clarity, offering Precigen SEC filings explained simply and in context.
Whether you need the latest Precigen quarterly earnings report 10-Q filing or an alert on Precigen Form 4 insider transactions real-time, our platform surfaces the data as soon as it hits EDGAR. Key features:
- AI-powered summaries that reduce a 300-page 10-K to bullet-point insights—Precigen annual report 10-K simplified
- One-click access to Precigen insider trading Form 4 transactions and executive stock patterns
- Contextual flags for 8-K trial updates—Precigen 8-K material events explained
- Real-time monitoring of cash burn, collaboration revenue, and segment results across filings
Use cases are practical: compare quarter-over-quarter R&D trends, track Precigen proxy statement executive compensation, or run a Precigen earnings report filing analysis before your next investment committee meeting. By understanding Precigen SEC documents with AI, investors quickly see how UltraVector manufacturing efficiency or AdenoVerse vaccine data affect valuation. No more page flipping—just the biotech insights that matter, delivered the moment PGEN files.
Precigen (PGEN) filed its Q3 2025 report highlighting a transition to commercialization after the FDA granted full approval in August for Papzimeos (zopapogene imadenovec) to treat recurrent respiratory papillomatosis. Q3 revenue was $2.9M, led by $1.8M of collaboration and licensing revenue recognized upon terminating a legacy PTC/Agilis agreement, with product and service revenue totaling $1.1M.
Operating expenses rose with launch preparation, including SG&A of $24.0M. The company reported a Q3 net loss of $146.3M, primarily driven by a non‑cash $111.5M loss from the change in fair value of warrant liabilities; a $179.0M deemed dividend on preferred stock increased the net loss attributable to common shareholders to $325.3M. Cash, cash equivalents and investments were $123.6M as of September 30, 2025, aided by a new $100.0M five‑year senior secured term loan to support the Papzimeos launch. Inventory of $3.1M was capitalized following approval. Common shares outstanding were 353,810,556 as of September 30, 2025.
PRECIGEN, Inc. (PGEN) Form 4: Director Jeffrey B. Kindler reported two separate sales of company common stock. On 09/29/2025 he sold 67,523 shares at a weighted-average price of $3.60, and on 09/30/2025 he sold 106,837 shares at a weighted-average price of $3.38. Following the 09/29/2025 sale his beneficial ownership in the reported class was 452,907 shares (direct). Following the 09/30/2025 sale his beneficial ownership was 346,070 shares (direct). The form includes explanatory footnotes that the reported prices are weighted averages across multiple transactions and that the filer will provide details on request. The Form 4 is signed by Jeffrey B. Kindler by attorney-in-fact Donald P. Lehr.
Precigen, Inc. reported a Form 144 notice for the proposed sale of 106,837 shares of its common stock, with an aggregate market value of $351,493.73, to be sold through Goldman Sachs & Co. LLC on or about 09/30/2025. The shares were acquired as restricted stock units on 03/09/2024 and were granted as compensation.
The filing also discloses a recent sale by the same person: 67,523 shares were sold on 09/29/2025 for gross proceeds of $241,104.38. The filer represents that they are not aware of any undisclosed material adverse information about the issuer.
Rutul R. Shah, Chief Operating Officer and director of Precigen, Inc. (PGEN), reported a purchase of 2,000 shares of Precigen common stock on 09/26/2025 at a reported price of $3.40 per share. After this transaction the reporting person beneficially owned 405,959 shares. The Form 4 was signed on behalf of Mr. Shah by an attorney-in-fact on 09/30/2025. The filing indicates the form was submitted by one reporting person and does not disclose any derivative transactions or additional changes to ownership beyond the common stock purchase.
Phil Tennant, Chief Commercial Officer of Precigen, Inc. (PGEN), reported an insider purchase. On 09/29/2025 he acquired 6,000 shares of Precigen common stock at $3.58 per share. Following the transaction he beneficially owned 65,031 shares. The Form 4 was signed on 09/30/2025 by an attorney-in-fact.
PRECIGEN, Inc. (PGEN) Form 144 notice shows a proposed sale of 67,523 shares of Common Stock through Goldman Sachs & Co. LLC on 09/29/2025 for an aggregate market value of $245,108.49. The filing states there are 352,910,331 shares outstanding, so the proposed sale represents approximately 0.019% of outstanding shares.
The shares were acquired as restricted stock awards or restricted stock units from the issuer between 03/23/2019 and 03/25/2021, in tranches of 7,911; 24,703; 34,328; and 581 shares. The filer reports nothing to report for securities sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Insider purchases by Precigen CFO increased his stake in the company. Harry Thomasian Jr. acquired 8,284 shares on 09/25/2025 at a weighted average price of $3.62 and 2,932 shares on 09/26/2025 at $3.42, bringing his total beneficial ownership to 468,626 shares. The filing shows the transactions were reported on Form 4 and the price for the 09/25 purchases is a weighted average of trades between $3.53 and $3.67. The report was signed on 09/26/2025 by an attorney-in-fact on behalf of the reporting person.
William H. Miller III Living Trust dated April 17, 2017 filed a Schedule 13G reporting beneficial ownership of 34,051,925 shares of Precigen, Inc. common stock, representing 9.2% of the class as presented in the filing. The reported amount includes 16,666,667 shares that the reporting person could acquire within 60 days upon exercise of warrants. The filing states the reporting person has sole voting and sole dispositive power over the reported shares.
The percent calculation in the filing is based on 298,455,084 shares outstanding plus an additional 54,937,411 shares delivered upon conversion of preferred stock and the 16,666,667 warrant shares referenced above. The trust certified the holdings are not intended to influence control of the issuer.
Randal J. Kirk and related entities updated their Schedule 13D/A for Precigen, Inc. (PGEN). The filing discloses that on September 17, 2025 the R.J. Kirk Declaration of Trust converted 25,000 shares of 8.00% Series A Convertible Perpetual Preferred Stock into 17,385,257 shares of Common Stock. Between September 18–19, 2025, Kapital Joe, LLC (under common control) sold 5,000,252 shares in open-market transactions for approximately $18,648,905.62. The cover-page holdings show Mr. Kirk with beneficial ownership of 146,295,359 shares (39.4%), RJ DOT 98,831,434 shares (26.6%), Sunset 2020 LLC 16,406,828 shares (4.4%), and Third Security, LLC 27,454,284 shares (7.4%). The filing also notes exercisable warrants (16,666,667) and options (906,512) included in Mr. Kirk's beneficial ownership calculation and incorporates prior amendments.
FAQ
What is the current stock price of Precigen (PGEN)?
What is the market cap of Precigen (PGEN)?
